Global Novel Antiviral Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Novel Antiviral Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The mechanism of action of antiviral drugs is mainly to inhibit the entry of viral particles into host cells and to inhibit the early stages of viral replication. There is also an inhibitor of DNA polymerase, which is mainly due to its ability to inhibit viral coding. At present, new antiviral drugs are actively seeking host factors, both in the initial stage of viral infection and in the later stages of nuclear transport of viral RNP complexes, to produce new drugs with new modes of action without drug resistance.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Novel Antiviral Drugs industry chain, the market status of Hepatitis Therapeutics (Reverse Transcriptase Inhibitors, Protease Inhibitors), HIV/AIDS Therapeutics (Reverse Transcriptase Inhibitors, Protease Inhibitors), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Novel Antiviral Drugs.
Regionally, the report analyzes the Novel Antiviral Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Novel Antiviral Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Novel Antiviral Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Novel Antiviral Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Reverse Transcriptase Inhibitors, Protease Inhibitors).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Novel Antiviral Drugs market.
Regional Analysis: The report involves examining the Novel Antiviral Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Novel Antiviral Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Novel Antiviral Drugs:
Company Analysis: Report covers individual Novel Antiviral Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Novel Antiviral Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hepatitis Therapeutics, HIV/AIDS Therapeutics).
Technology Analysis: Report covers specific technologies relevant to Novel Antiviral Drugs. It assesses the current state, advancements, and potential future developments in Novel Antiviral Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Novel Antiviral Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Novel Antiviral Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Novel Antiviral Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Novel Antiviral Drugs, with revenue, gross margin and global market share of Novel Antiviral Drugs from 2019 to 2024.
Chapter 3, the Novel Antiviral Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Novel Antiviral Drugs market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Novel Antiviral Drugs.
Chapter 13, to describe Novel Antiviral Drugs research findings and conclusion.
The mechanism of action of antiviral drugs is mainly to inhibit the entry of viral particles into host cells and to inhibit the early stages of viral replication. There is also an inhibitor of DNA polymerase, which is mainly due to its ability to inhibit viral coding. At present, new antiviral drugs are actively seeking host factors, both in the initial stage of viral infection and in the later stages of nuclear transport of viral RNP complexes, to produce new drugs with new modes of action without drug resistance.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Novel Antiviral Drugs industry chain, the market status of Hepatitis Therapeutics (Reverse Transcriptase Inhibitors, Protease Inhibitors), HIV/AIDS Therapeutics (Reverse Transcriptase Inhibitors, Protease Inhibitors), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Novel Antiviral Drugs.
Regionally, the report analyzes the Novel Antiviral Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Novel Antiviral Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Novel Antiviral Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Novel Antiviral Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Reverse Transcriptase Inhibitors, Protease Inhibitors).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Novel Antiviral Drugs market.
Regional Analysis: The report involves examining the Novel Antiviral Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Novel Antiviral Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Novel Antiviral Drugs:
Company Analysis: Report covers individual Novel Antiviral Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Novel Antiviral Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hepatitis Therapeutics, HIV/AIDS Therapeutics).
Technology Analysis: Report covers specific technologies relevant to Novel Antiviral Drugs. It assesses the current state, advancements, and potential future developments in Novel Antiviral Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Novel Antiviral Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Novel Antiviral Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Fusion Inhibitors
- Immune System Modulators
- Other
- Hepatitis Therapeutics
- HIV/AIDS Therapeutics
- Herpes Therapeutics
- Influenza Therapeutics
- Other
- Roche Holding AG
- GlaxoSmithKline
- Bristol-Myers Squibb
- AbbVie
- Johnson & Johnson
- Merck & Co
- Novartis
- Dr Reddy’s
- Gilead Sciences
- Aurobindo Pharma
- Cipla
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Novel Antiviral Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Novel Antiviral Drugs, with revenue, gross margin and global market share of Novel Antiviral Drugs from 2019 to 2024.
Chapter 3, the Novel Antiviral Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Novel Antiviral Drugs market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Novel Antiviral Drugs.
Chapter 13, to describe Novel Antiviral Drugs research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Novel Antiviral Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Novel Antiviral Drugs by Type
1.3.1 Overview: Global Novel Antiviral Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Novel Antiviral Drugs Consumption Value Market Share by Type in 2023
1.3.3 Reverse Transcriptase Inhibitors
1.3.4 Protease Inhibitors
1.3.5 Fusion Inhibitors
1.3.6 Immune System Modulators
1.3.7 Other
1.4 Global Novel Antiviral Drugs Market by Application
1.4.1 Overview: Global Novel Antiviral Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hepatitis Therapeutics
1.4.3 HIV/AIDS Therapeutics
1.4.4 Herpes Therapeutics
1.4.5 Influenza Therapeutics
1.4.6 Other
1.5 Global Novel Antiviral Drugs Market Size & Forecast
1.6 Global Novel Antiviral Drugs Market Size and Forecast by Region
1.6.1 Global Novel Antiviral Drugs Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Novel Antiviral Drugs Market Size by Region, (2019-2030)
1.6.3 North America Novel Antiviral Drugs Market Size and Prospect (2019-2030)
1.6.4 Europe Novel Antiviral Drugs Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Novel Antiviral Drugs Market Size and Prospect (2019-2030)
1.6.6 South America Novel Antiviral Drugs Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Novel Antiviral Drugs Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Roche Holding AG
2.1.1 Roche Holding AG Details
2.1.2 Roche Holding AG Major Business
2.1.3 Roche Holding AG Novel Antiviral Drugs Product and Solutions
2.1.4 Roche Holding AG Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Roche Holding AG Recent Developments and Future Plans
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Novel Antiviral Drugs Product and Solutions
2.2.4 GlaxoSmithKline Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GlaxoSmithKline Recent Developments and Future Plans
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business
2.3.3 Bristol-Myers Squibb Novel Antiviral Drugs Product and Solutions
2.3.4 Bristol-Myers Squibb Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.4 AbbVie
2.4.1 AbbVie Details
2.4.2 AbbVie Major Business
2.4.3 AbbVie Novel Antiviral Drugs Product and Solutions
2.4.4 AbbVie Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 AbbVie Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Novel Antiviral Drugs Product and Solutions
2.5.4 Johnson & Johnson Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Merck & Co
2.6.1 Merck & Co Details
2.6.2 Merck & Co Major Business
2.6.3 Merck & Co Novel Antiviral Drugs Product and Solutions
2.6.4 Merck & Co Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Merck & Co Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Novel Antiviral Drugs Product and Solutions
2.7.4 Novartis Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Dr Reddy’s
2.8.1 Dr Reddy’s Details
2.8.2 Dr Reddy’s Major Business
2.8.3 Dr Reddy’s Novel Antiviral Drugs Product and Solutions
2.8.4 Dr Reddy’s Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Dr Reddy’s Recent Developments and Future Plans
2.9 Gilead Sciences
2.9.1 Gilead Sciences Details
2.9.2 Gilead Sciences Major Business
2.9.3 Gilead Sciences Novel Antiviral Drugs Product and Solutions
2.9.4 Gilead Sciences Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Gilead Sciences Recent Developments and Future Plans
2.10 Aurobindo Pharma
2.10.1 Aurobindo Pharma Details
2.10.2 Aurobindo Pharma Major Business
2.10.3 Aurobindo Pharma Novel Antiviral Drugs Product and Solutions
2.10.4 Aurobindo Pharma Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Aurobindo Pharma Recent Developments and Future Plans
2.11 Cipla
2.11.1 Cipla Details
2.11.2 Cipla Major Business
2.11.3 Cipla Novel Antiviral Drugs Product and Solutions
2.11.4 Cipla Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Cipla Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Novel Antiviral Drugs Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Novel Antiviral Drugs by Company Revenue
3.2.2 Top 3 Novel Antiviral Drugs Players Market Share in 2023
3.2.3 Top 6 Novel Antiviral Drugs Players Market Share in 2023
3.3 Novel Antiviral Drugs Market: Overall Company Footprint Analysis
3.3.1 Novel Antiviral Drugs Market: Region Footprint
3.3.2 Novel Antiviral Drugs Market: Company Product Type Footprint
3.3.3 Novel Antiviral Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Novel Antiviral Drugs Consumption Value and Market Share by Type (2019-2024)
4.2 Global Novel Antiviral Drugs Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2024)
5.2 Global Novel Antiviral Drugs Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Novel Antiviral Drugs Consumption Value by Type (2019-2030)
6.2 North America Novel Antiviral Drugs Consumption Value by Application (2019-2030)
6.3 North America Novel Antiviral Drugs Market Size by Country
6.3.1 North America Novel Antiviral Drugs Consumption Value by Country (2019-2030)
6.3.2 United States Novel Antiviral Drugs Market Size and Forecast (2019-2030)
6.3.3 Canada Novel Antiviral Drugs Market Size and Forecast (2019-2030)
6.3.4 Mexico Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Novel Antiviral Drugs Consumption Value by Type (2019-2030)
7.2 Europe Novel Antiviral Drugs Consumption Value by Application (2019-2030)
7.3 Europe Novel Antiviral Drugs Market Size by Country
7.3.1 Europe Novel Antiviral Drugs Consumption Value by Country (2019-2030)
7.3.2 Germany Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7.3.3 France Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7.3.5 Russia Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7.3.6 Italy Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Novel Antiviral Drugs Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Novel Antiviral Drugs Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Novel Antiviral Drugs Market Size by Region
8.3.1 Asia-Pacific Novel Antiviral Drugs Consumption Value by Region (2019-2030)
8.3.2 China Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.3 Japan Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.4 South Korea Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.5 India Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.7 Australia Novel Antiviral Drugs Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Novel Antiviral Drugs Consumption Value by Type (2019-2030)
9.2 South America Novel Antiviral Drugs Consumption Value by Application (2019-2030)
9.3 South America Novel Antiviral Drugs Market Size by Country
9.3.1 South America Novel Antiviral Drugs Consumption Value by Country (2019-2030)
9.3.2 Brazil Novel Antiviral Drugs Market Size and Forecast (2019-2030)
9.3.3 Argentina Novel Antiviral Drugs Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Novel Antiviral Drugs Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Novel Antiviral Drugs Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Novel Antiviral Drugs Market Size by Country
10.3.1 Middle East & Africa Novel Antiviral Drugs Consumption Value by Country (2019-2030)
10.3.2 Turkey Novel Antiviral Drugs Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Novel Antiviral Drugs Market Size and Forecast (2019-2030)
10.3.4 UAE Novel Antiviral Drugs Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Novel Antiviral Drugs Market Drivers
11.2 Novel Antiviral Drugs Market Restraints
11.3 Novel Antiviral Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Novel Antiviral Drugs Industry Chain
12.2 Novel Antiviral Drugs Upstream Analysis
12.3 Novel Antiviral Drugs Midstream Analysis
12.4 Novel Antiviral Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Novel Antiviral Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Novel Antiviral Drugs by Type
1.3.1 Overview: Global Novel Antiviral Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Novel Antiviral Drugs Consumption Value Market Share by Type in 2023
1.3.3 Reverse Transcriptase Inhibitors
1.3.4 Protease Inhibitors
1.3.5 Fusion Inhibitors
1.3.6 Immune System Modulators
1.3.7 Other
1.4 Global Novel Antiviral Drugs Market by Application
1.4.1 Overview: Global Novel Antiviral Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hepatitis Therapeutics
1.4.3 HIV/AIDS Therapeutics
1.4.4 Herpes Therapeutics
1.4.5 Influenza Therapeutics
1.4.6 Other
1.5 Global Novel Antiviral Drugs Market Size & Forecast
1.6 Global Novel Antiviral Drugs Market Size and Forecast by Region
1.6.1 Global Novel Antiviral Drugs Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Novel Antiviral Drugs Market Size by Region, (2019-2030)
1.6.3 North America Novel Antiviral Drugs Market Size and Prospect (2019-2030)
1.6.4 Europe Novel Antiviral Drugs Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Novel Antiviral Drugs Market Size and Prospect (2019-2030)
1.6.6 South America Novel Antiviral Drugs Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Novel Antiviral Drugs Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Roche Holding AG
2.1.1 Roche Holding AG Details
2.1.2 Roche Holding AG Major Business
2.1.3 Roche Holding AG Novel Antiviral Drugs Product and Solutions
2.1.4 Roche Holding AG Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Roche Holding AG Recent Developments and Future Plans
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Novel Antiviral Drugs Product and Solutions
2.2.4 GlaxoSmithKline Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GlaxoSmithKline Recent Developments and Future Plans
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business
2.3.3 Bristol-Myers Squibb Novel Antiviral Drugs Product and Solutions
2.3.4 Bristol-Myers Squibb Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.4 AbbVie
2.4.1 AbbVie Details
2.4.2 AbbVie Major Business
2.4.3 AbbVie Novel Antiviral Drugs Product and Solutions
2.4.4 AbbVie Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 AbbVie Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Novel Antiviral Drugs Product and Solutions
2.5.4 Johnson & Johnson Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Merck & Co
2.6.1 Merck & Co Details
2.6.2 Merck & Co Major Business
2.6.3 Merck & Co Novel Antiviral Drugs Product and Solutions
2.6.4 Merck & Co Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Merck & Co Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Novel Antiviral Drugs Product and Solutions
2.7.4 Novartis Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Dr Reddy’s
2.8.1 Dr Reddy’s Details
2.8.2 Dr Reddy’s Major Business
2.8.3 Dr Reddy’s Novel Antiviral Drugs Product and Solutions
2.8.4 Dr Reddy’s Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Dr Reddy’s Recent Developments and Future Plans
2.9 Gilead Sciences
2.9.1 Gilead Sciences Details
2.9.2 Gilead Sciences Major Business
2.9.3 Gilead Sciences Novel Antiviral Drugs Product and Solutions
2.9.4 Gilead Sciences Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Gilead Sciences Recent Developments and Future Plans
2.10 Aurobindo Pharma
2.10.1 Aurobindo Pharma Details
2.10.2 Aurobindo Pharma Major Business
2.10.3 Aurobindo Pharma Novel Antiviral Drugs Product and Solutions
2.10.4 Aurobindo Pharma Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Aurobindo Pharma Recent Developments and Future Plans
2.11 Cipla
2.11.1 Cipla Details
2.11.2 Cipla Major Business
2.11.3 Cipla Novel Antiviral Drugs Product and Solutions
2.11.4 Cipla Novel Antiviral Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Cipla Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Novel Antiviral Drugs Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Novel Antiviral Drugs by Company Revenue
3.2.2 Top 3 Novel Antiviral Drugs Players Market Share in 2023
3.2.3 Top 6 Novel Antiviral Drugs Players Market Share in 2023
3.3 Novel Antiviral Drugs Market: Overall Company Footprint Analysis
3.3.1 Novel Antiviral Drugs Market: Region Footprint
3.3.2 Novel Antiviral Drugs Market: Company Product Type Footprint
3.3.3 Novel Antiviral Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Novel Antiviral Drugs Consumption Value and Market Share by Type (2019-2024)
4.2 Global Novel Antiviral Drugs Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2024)
5.2 Global Novel Antiviral Drugs Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Novel Antiviral Drugs Consumption Value by Type (2019-2030)
6.2 North America Novel Antiviral Drugs Consumption Value by Application (2019-2030)
6.3 North America Novel Antiviral Drugs Market Size by Country
6.3.1 North America Novel Antiviral Drugs Consumption Value by Country (2019-2030)
6.3.2 United States Novel Antiviral Drugs Market Size and Forecast (2019-2030)
6.3.3 Canada Novel Antiviral Drugs Market Size and Forecast (2019-2030)
6.3.4 Mexico Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Novel Antiviral Drugs Consumption Value by Type (2019-2030)
7.2 Europe Novel Antiviral Drugs Consumption Value by Application (2019-2030)
7.3 Europe Novel Antiviral Drugs Market Size by Country
7.3.1 Europe Novel Antiviral Drugs Consumption Value by Country (2019-2030)
7.3.2 Germany Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7.3.3 France Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7.3.5 Russia Novel Antiviral Drugs Market Size and Forecast (2019-2030)
7.3.6 Italy Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Novel Antiviral Drugs Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Novel Antiviral Drugs Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Novel Antiviral Drugs Market Size by Region
8.3.1 Asia-Pacific Novel Antiviral Drugs Consumption Value by Region (2019-2030)
8.3.2 China Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.3 Japan Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.4 South Korea Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.5 India Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Novel Antiviral Drugs Market Size and Forecast (2019-2030)
8.3.7 Australia Novel Antiviral Drugs Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Novel Antiviral Drugs Consumption Value by Type (2019-2030)
9.2 South America Novel Antiviral Drugs Consumption Value by Application (2019-2030)
9.3 South America Novel Antiviral Drugs Market Size by Country
9.3.1 South America Novel Antiviral Drugs Consumption Value by Country (2019-2030)
9.3.2 Brazil Novel Antiviral Drugs Market Size and Forecast (2019-2030)
9.3.3 Argentina Novel Antiviral Drugs Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Novel Antiviral Drugs Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Novel Antiviral Drugs Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Novel Antiviral Drugs Market Size by Country
10.3.1 Middle East & Africa Novel Antiviral Drugs Consumption Value by Country (2019-2030)
10.3.2 Turkey Novel Antiviral Drugs Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Novel Antiviral Drugs Market Size and Forecast (2019-2030)
10.3.4 UAE Novel Antiviral Drugs Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Novel Antiviral Drugs Market Drivers
11.2 Novel Antiviral Drugs Market Restraints
11.3 Novel Antiviral Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Novel Antiviral Drugs Industry Chain
12.2 Novel Antiviral Drugs Upstream Analysis
12.3 Novel Antiviral Drugs Midstream Analysis
12.4 Novel Antiviral Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Novel Antiviral Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Novel Antiviral Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Novel Antiviral Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Novel Antiviral Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Roche Holding AG Company Information, Head Office, and Major Competitors
Table 6. Roche Holding AG Major Business
Table 7. Roche Holding AG Novel Antiviral Drugs Product and Solutions
Table 8. Roche Holding AG Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Roche Holding AG Recent Developments and Future Plans
Table 10. GlaxoSmithKline Company Information, Head Office, and Major Competitors
Table 11. GlaxoSmithKline Major Business
Table 12. GlaxoSmithKline Novel Antiviral Drugs Product and Solutions
Table 13. GlaxoSmithKline Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. GlaxoSmithKline Recent Developments and Future Plans
Table 15. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 16. Bristol-Myers Squibb Major Business
Table 17. Bristol-Myers Squibb Novel Antiviral Drugs Product and Solutions
Table 18. Bristol-Myers Squibb Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Bristol-Myers Squibb Recent Developments and Future Plans
Table 20. AbbVie Company Information, Head Office, and Major Competitors
Table 21. AbbVie Major Business
Table 22. AbbVie Novel Antiviral Drugs Product and Solutions
Table 23. AbbVie Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. AbbVie Recent Developments and Future Plans
Table 25. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 26. Johnson & Johnson Major Business
Table 27. Johnson & Johnson Novel Antiviral Drugs Product and Solutions
Table 28. Johnson & Johnson Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Johnson & Johnson Recent Developments and Future Plans
Table 30. Merck & Co Company Information, Head Office, and Major Competitors
Table 31. Merck & Co Major Business
Table 32. Merck & Co Novel Antiviral Drugs Product and Solutions
Table 33. Merck & Co Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Merck & Co Recent Developments and Future Plans
Table 35. Novartis Company Information, Head Office, and Major Competitors
Table 36. Novartis Major Business
Table 37. Novartis Novel Antiviral Drugs Product and Solutions
Table 38. Novartis Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Novartis Recent Developments and Future Plans
Table 40. Dr Reddy’s Company Information, Head Office, and Major Competitors
Table 41. Dr Reddy’s Major Business
Table 42. Dr Reddy’s Novel Antiviral Drugs Product and Solutions
Table 43. Dr Reddy’s Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Dr Reddy’s Recent Developments and Future Plans
Table 45. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 46. Gilead Sciences Major Business
Table 47. Gilead Sciences Novel Antiviral Drugs Product and Solutions
Table 48. Gilead Sciences Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Gilead Sciences Recent Developments and Future Plans
Table 50. Aurobindo Pharma Company Information, Head Office, and Major Competitors
Table 51. Aurobindo Pharma Major Business
Table 52. Aurobindo Pharma Novel Antiviral Drugs Product and Solutions
Table 53. Aurobindo Pharma Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Aurobindo Pharma Recent Developments and Future Plans
Table 55. Cipla Company Information, Head Office, and Major Competitors
Table 56. Cipla Major Business
Table 57. Cipla Novel Antiviral Drugs Product and Solutions
Table 58. Cipla Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Cipla Recent Developments and Future Plans
Table 60. Global Novel Antiviral Drugs Revenue (USD Million) by Players (2019-2024)
Table 61. Global Novel Antiviral Drugs Revenue Share by Players (2019-2024)
Table 62. Breakdown of Novel Antiviral Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in Novel Antiviral Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 64. Head Office of Key Novel Antiviral Drugs Players
Table 65. Novel Antiviral Drugs Market: Company Product Type Footprint
Table 66. Novel Antiviral Drugs Market: Company Product Application Footprint
Table 67. Novel Antiviral Drugs New Market Entrants and Barriers to Market Entry
Table 68. Novel Antiviral Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global Novel Antiviral Drugs Consumption Value (USD Million) by Type (2019-2024)
Table 70. Global Novel Antiviral Drugs Consumption Value Share by Type (2019-2024)
Table 71. Global Novel Antiviral Drugs Consumption Value Forecast by Type (2025-2030)
Table 72. Global Novel Antiviral Drugs Consumption Value by Application (2019-2024)
Table 73. Global Novel Antiviral Drugs Consumption Value Forecast by Application (2025-2030)
Table 74. North America Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 75. North America Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 76. North America Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 77. North America Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 78. North America Novel Antiviral Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 79. North America Novel Antiviral Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 80. Europe Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Europe Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Europe Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 83. Europe Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 84. Europe Novel Antiviral Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe Novel Antiviral Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 87. Asia-Pacific Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 88. Asia-Pacific Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 89. Asia-Pacific Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 90. Asia-Pacific Novel Antiviral Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 91. Asia-Pacific Novel Antiviral Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 92. South America Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 93. South America Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 94. South America Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 95. South America Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 96. South America Novel Antiviral Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 97. South America Novel Antiviral Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Middle East & Africa Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 99. Middle East & Africa Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 100. Middle East & Africa Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 101. Middle East & Africa Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 102. Middle East & Africa Novel Antiviral Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 103. Middle East & Africa Novel Antiviral Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 104. Novel Antiviral Drugs Raw Material
Table 105. Key Suppliers of Novel Antiviral Drugs Raw Materials
Table 1. Global Novel Antiviral Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Novel Antiviral Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Novel Antiviral Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Novel Antiviral Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Roche Holding AG Company Information, Head Office, and Major Competitors
Table 6. Roche Holding AG Major Business
Table 7. Roche Holding AG Novel Antiviral Drugs Product and Solutions
Table 8. Roche Holding AG Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Roche Holding AG Recent Developments and Future Plans
Table 10. GlaxoSmithKline Company Information, Head Office, and Major Competitors
Table 11. GlaxoSmithKline Major Business
Table 12. GlaxoSmithKline Novel Antiviral Drugs Product and Solutions
Table 13. GlaxoSmithKline Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. GlaxoSmithKline Recent Developments and Future Plans
Table 15. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 16. Bristol-Myers Squibb Major Business
Table 17. Bristol-Myers Squibb Novel Antiviral Drugs Product and Solutions
Table 18. Bristol-Myers Squibb Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Bristol-Myers Squibb Recent Developments and Future Plans
Table 20. AbbVie Company Information, Head Office, and Major Competitors
Table 21. AbbVie Major Business
Table 22. AbbVie Novel Antiviral Drugs Product and Solutions
Table 23. AbbVie Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. AbbVie Recent Developments and Future Plans
Table 25. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 26. Johnson & Johnson Major Business
Table 27. Johnson & Johnson Novel Antiviral Drugs Product and Solutions
Table 28. Johnson & Johnson Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Johnson & Johnson Recent Developments and Future Plans
Table 30. Merck & Co Company Information, Head Office, and Major Competitors
Table 31. Merck & Co Major Business
Table 32. Merck & Co Novel Antiviral Drugs Product and Solutions
Table 33. Merck & Co Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Merck & Co Recent Developments and Future Plans
Table 35. Novartis Company Information, Head Office, and Major Competitors
Table 36. Novartis Major Business
Table 37. Novartis Novel Antiviral Drugs Product and Solutions
Table 38. Novartis Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Novartis Recent Developments and Future Plans
Table 40. Dr Reddy’s Company Information, Head Office, and Major Competitors
Table 41. Dr Reddy’s Major Business
Table 42. Dr Reddy’s Novel Antiviral Drugs Product and Solutions
Table 43. Dr Reddy’s Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Dr Reddy’s Recent Developments and Future Plans
Table 45. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 46. Gilead Sciences Major Business
Table 47. Gilead Sciences Novel Antiviral Drugs Product and Solutions
Table 48. Gilead Sciences Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Gilead Sciences Recent Developments and Future Plans
Table 50. Aurobindo Pharma Company Information, Head Office, and Major Competitors
Table 51. Aurobindo Pharma Major Business
Table 52. Aurobindo Pharma Novel Antiviral Drugs Product and Solutions
Table 53. Aurobindo Pharma Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Aurobindo Pharma Recent Developments and Future Plans
Table 55. Cipla Company Information, Head Office, and Major Competitors
Table 56. Cipla Major Business
Table 57. Cipla Novel Antiviral Drugs Product and Solutions
Table 58. Cipla Novel Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Cipla Recent Developments and Future Plans
Table 60. Global Novel Antiviral Drugs Revenue (USD Million) by Players (2019-2024)
Table 61. Global Novel Antiviral Drugs Revenue Share by Players (2019-2024)
Table 62. Breakdown of Novel Antiviral Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in Novel Antiviral Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 64. Head Office of Key Novel Antiviral Drugs Players
Table 65. Novel Antiviral Drugs Market: Company Product Type Footprint
Table 66. Novel Antiviral Drugs Market: Company Product Application Footprint
Table 67. Novel Antiviral Drugs New Market Entrants and Barriers to Market Entry
Table 68. Novel Antiviral Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global Novel Antiviral Drugs Consumption Value (USD Million) by Type (2019-2024)
Table 70. Global Novel Antiviral Drugs Consumption Value Share by Type (2019-2024)
Table 71. Global Novel Antiviral Drugs Consumption Value Forecast by Type (2025-2030)
Table 72. Global Novel Antiviral Drugs Consumption Value by Application (2019-2024)
Table 73. Global Novel Antiviral Drugs Consumption Value Forecast by Application (2025-2030)
Table 74. North America Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 75. North America Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 76. North America Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 77. North America Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 78. North America Novel Antiviral Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 79. North America Novel Antiviral Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 80. Europe Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Europe Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Europe Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 83. Europe Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 84. Europe Novel Antiviral Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe Novel Antiviral Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 87. Asia-Pacific Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 88. Asia-Pacific Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 89. Asia-Pacific Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 90. Asia-Pacific Novel Antiviral Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 91. Asia-Pacific Novel Antiviral Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 92. South America Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 93. South America Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 94. South America Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 95. South America Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 96. South America Novel Antiviral Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 97. South America Novel Antiviral Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Middle East & Africa Novel Antiviral Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 99. Middle East & Africa Novel Antiviral Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 100. Middle East & Africa Novel Antiviral Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 101. Middle East & Africa Novel Antiviral Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 102. Middle East & Africa Novel Antiviral Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 103. Middle East & Africa Novel Antiviral Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 104. Novel Antiviral Drugs Raw Material
Table 105. Key Suppliers of Novel Antiviral Drugs Raw Materials
LIST OF FIGURES
Figure 1. Novel Antiviral Drugs Picture
Figure 2. Global Novel Antiviral Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Novel Antiviral Drugs Consumption Value Market Share by Type in 2023
Figure 4. Reverse Transcriptase Inhibitors
Figure 5. Protease Inhibitors
Figure 6. Fusion Inhibitors
Figure 7. Immune System Modulators
Figure 8. Other
Figure 9. Global Novel Antiviral Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 10. Novel Antiviral Drugs Consumption Value Market Share by Application in 2023
Figure 11. Hepatitis Therapeutics Picture
Figure 12. HIV/AIDS Therapeutics Picture
Figure 13. Herpes Therapeutics Picture
Figure 14. Influenza Therapeutics Picture
Figure 15. Other Picture
Figure 16. Global Novel Antiviral Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 17. Global Novel Antiviral Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 18. Global Market Novel Antiviral Drugs Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 19. Global Novel Antiviral Drugs Consumption Value Market Share by Region (2019-2030)
Figure 20. Global Novel Antiviral Drugs Consumption Value Market Share by Region in 2023
Figure 21. North America Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 22. Europe Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 23. Asia-Pacific Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 24. South America Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 25. Middle East and Africa Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 26. Global Novel Antiviral Drugs Revenue Share by Players in 2023
Figure 27. Novel Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 28. Global Top 3 Players Novel Antiviral Drugs Market Share in 2023
Figure 29. Global Top 6 Players Novel Antiviral Drugs Market Share in 2023
Figure 30. Global Novel Antiviral Drugs Consumption Value Share by Type (2019-2024)
Figure 31. Global Novel Antiviral Drugs Market Share Forecast by Type (2025-2030)
Figure 32. Global Novel Antiviral Drugs Consumption Value Share by Application (2019-2024)
Figure 33. Global Novel Antiviral Drugs Market Share Forecast by Application (2025-2030)
Figure 34. North America Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 35. North America Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 36. North America Novel Antiviral Drugs Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 38. Canada Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 39. Mexico Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 40. Europe Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 41. Europe Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 42. Europe Novel Antiviral Drugs Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 44. France Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 45. United Kingdom Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 46. Russia Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 47. Italy Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Novel Antiviral Drugs Consumption Value Market Share by Region (2019-2030)
Figure 51. China Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 52. Japan Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 53. South Korea Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 54. India Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 55. Southeast Asia Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 56. Australia Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 57. South America Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 58. South America Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 59. South America Novel Antiviral Drugs Consumption Value Market Share by Country (2019-2030)
Figure 60. Brazil Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 61. Argentina Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 62. Middle East and Africa Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 63. Middle East and Africa Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 64. Middle East and Africa Novel Antiviral Drugs Consumption Value Market Share by Country (2019-2030)
Figure 65. Turkey Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 66. Saudi Arabia Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 67. UAE Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 68. Novel Antiviral Drugs Market Drivers
Figure 69. Novel Antiviral Drugs Market Restraints
Figure 70. Novel Antiviral Drugs Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Manufacturing Cost Structure Analysis of Novel Antiviral Drugs in 2023
Figure 73. Manufacturing Process Analysis of Novel Antiviral Drugs
Figure 74. Novel Antiviral Drugs Industrial Chain
Figure 75. Methodology
Figure 76. Research Process and Data Source
Figure 1. Novel Antiviral Drugs Picture
Figure 2. Global Novel Antiviral Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Novel Antiviral Drugs Consumption Value Market Share by Type in 2023
Figure 4. Reverse Transcriptase Inhibitors
Figure 5. Protease Inhibitors
Figure 6. Fusion Inhibitors
Figure 7. Immune System Modulators
Figure 8. Other
Figure 9. Global Novel Antiviral Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 10. Novel Antiviral Drugs Consumption Value Market Share by Application in 2023
Figure 11. Hepatitis Therapeutics Picture
Figure 12. HIV/AIDS Therapeutics Picture
Figure 13. Herpes Therapeutics Picture
Figure 14. Influenza Therapeutics Picture
Figure 15. Other Picture
Figure 16. Global Novel Antiviral Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 17. Global Novel Antiviral Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 18. Global Market Novel Antiviral Drugs Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 19. Global Novel Antiviral Drugs Consumption Value Market Share by Region (2019-2030)
Figure 20. Global Novel Antiviral Drugs Consumption Value Market Share by Region in 2023
Figure 21. North America Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 22. Europe Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 23. Asia-Pacific Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 24. South America Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 25. Middle East and Africa Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 26. Global Novel Antiviral Drugs Revenue Share by Players in 2023
Figure 27. Novel Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 28. Global Top 3 Players Novel Antiviral Drugs Market Share in 2023
Figure 29. Global Top 6 Players Novel Antiviral Drugs Market Share in 2023
Figure 30. Global Novel Antiviral Drugs Consumption Value Share by Type (2019-2024)
Figure 31. Global Novel Antiviral Drugs Market Share Forecast by Type (2025-2030)
Figure 32. Global Novel Antiviral Drugs Consumption Value Share by Application (2019-2024)
Figure 33. Global Novel Antiviral Drugs Market Share Forecast by Application (2025-2030)
Figure 34. North America Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 35. North America Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 36. North America Novel Antiviral Drugs Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 38. Canada Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 39. Mexico Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 40. Europe Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 41. Europe Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 42. Europe Novel Antiviral Drugs Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 44. France Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 45. United Kingdom Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 46. Russia Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 47. Italy Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Novel Antiviral Drugs Consumption Value Market Share by Region (2019-2030)
Figure 51. China Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 52. Japan Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 53. South Korea Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 54. India Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 55. Southeast Asia Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 56. Australia Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 57. South America Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 58. South America Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 59. South America Novel Antiviral Drugs Consumption Value Market Share by Country (2019-2030)
Figure 60. Brazil Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 61. Argentina Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 62. Middle East and Africa Novel Antiviral Drugs Consumption Value Market Share by Type (2019-2030)
Figure 63. Middle East and Africa Novel Antiviral Drugs Consumption Value Market Share by Application (2019-2030)
Figure 64. Middle East and Africa Novel Antiviral Drugs Consumption Value Market Share by Country (2019-2030)
Figure 65. Turkey Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 66. Saudi Arabia Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 67. UAE Novel Antiviral Drugs Consumption Value (2019-2030) & (USD Million)
Figure 68. Novel Antiviral Drugs Market Drivers
Figure 69. Novel Antiviral Drugs Market Restraints
Figure 70. Novel Antiviral Drugs Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Manufacturing Cost Structure Analysis of Novel Antiviral Drugs in 2023
Figure 73. Manufacturing Process Analysis of Novel Antiviral Drugs
Figure 74. Novel Antiviral Drugs Industrial Chain
Figure 75. Methodology
Figure 76. Research Process and Data Source
